文献速递脊柱关节炎

阿普米司特单药治疗未使用过改善病情抗风湿药的银屑病关节炎患者:随机安慰剂对照PALACE 4试验结果

Apremilast monotherapy in DMARD-naive psoriatic arthritis patients: results of the randomized, placebo-controlled PALACE 4 trial.
PubMed 文献 · Rheumatology (Oxford) · 2018-01-01

PALACE 4试验将527例未使用过改善病情抗风湿药的活动性银屑病关节炎患者按1:1:1随机分配至安慰剂组、阿普米司特20 mg每日两次组或30 mg每日两次组。第16周阿普米司特20 mg组和30 mg组ACR20应答率分别为28.0%和30.7%,均高于安慰剂组的15.9%;HAQ-DI评分改善也优于安慰剂,疗效持续至第52周,总体耐受性良好。

要点

  • 第16周ACR20应答率:安慰剂组15.9%,阿普米司特20 mg组28.0%(P=0.0062),30 mg组30.7%(P=0.0010)。
  • 第16周HAQ-DI评分平均改善:阿普米司特20 mg组-0.17(P=0.0008),30 mg组-0.21(P<0.0001),安慰剂组0.03。
  • 52周内常见不良事件为腹泻、恶心、头痛和上呼吸道感染,多为轻中度,严重不良事件和导致停药的不良事件组间相当。

核心结论

  • 在未使用过改善病情抗风湿药的患者中,阿普米司特单药治疗可改善银屑病关节炎的体征和症状,疗效持续至52周,且总体耐受性良好。

研究设计与样本

  • PALACE 4为随机、安慰剂对照试验,纳入未使用过改善病情抗风湿药的活动性银屑病关节炎患者,按1:1:1随机分配至安慰剂组、阿普米司特20 mg每日两次组或30 mg每日两次组。
  • 第16周或第24周时安慰剂组患者重新随机分配至阿普米司特治疗,双盲阿普米司特治疗持续至第52周,延伸期最长至4年。
  • 共527例患者随机分组并接受治疗,平均病程3.4年,疾病活动度高。

主要发现

  • 第16周达到ACR20应答的患者比例:安慰剂组15.9%,阿普米司特20 mg组28.0%(P=0.0062),30 mg组30.7%(P=0.0010)。
  • 第16周HAQ-DI评分平均改善:阿普米司特20 mg组-0.17(P=0.0008),30 mg组-0.21(P<0.0001),安慰剂组0.03。
  • 两种阿普米司特剂量在第16周均较安慰剂显示显著的ACR50应答,并在次要疗效指标(肿胀/压痛关节计数)和银屑病评估方面改善,改善持续至第52周。
  • 52周内常见不良事件为腹泻、恶心、头痛和上呼吸道感染,大多数事件为轻度或中度;严重不良事件和导致停药的不良事件组间相当;实验室异常不常见且为一过性。

关键数值与推荐

  • 主要终点为第16周达到ACR20应答的患者比例。
  • 次要终点包括第16周HAQ残疾指数(HAQ-DI)评分的平均变化。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The PALACE 4 trial evaluated apremilast monotherapy in patients with active PsA who were DMARD-naive. METHODS: Eligible patients were randomized (1:1:1) to placebo, apremilast 20 mg twice a day or apremilast 30 mg twice a day. At week 16 or 24, placebo patients were rerandomized to apremilast. Double-blind apremilast treatment continued to week 52, with extension up to 4 years. The primary endpoint was the proportion of patients achieving ⩾20% improvement in ACR response criteria (ACR20) at week 16; secondary endpoints included the mean change in the HAQ Disability Index (HAQ-DI) score at week 16. RESULTS: A total of 527 patients with mean disease duration of 3.4 years and high disease activity were randomized and received treatment. More apremilast patients achieved ACR20 response at week 16 [placebo, 15.9%; 20 mg, 28.0% (P = 0.0062); 30 mg, 30.7% (P = 0.0010)]. The mean HAQ-DI improvements were -0.17 (20 mg; P = 0.0008) and -0.21 (30 mg; P < 0.0001) vs 0.03 (placebo). Both apremilast doses showed significant ACR50 responses vs placebo at week 16 and improvements in secondary efficacy measures (swollen/tender joint counts) and psoriasis assessments, with sustained improvements through week 52. Common adverse events (AEs) over 52 weeks were diarrhoea, nausea, headache and upper respiratory tract infection; most events were mild or moderate. Serious AEs and AEs leading to discontinuation were comparable between groups. Laboratory abnormalities were infrequent and transient. CONCLUSIONS: In DMARD-naive patients, apremilast monotherapy improved PsA signs/symptoms over 52 weeks and was generally well tolerated. TRIAL REGISTRATION: ClinicalTrials.gov (http://clinicaltrials.gov), NCT01307423.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Wells AF, Edwards CJ, Kivitz AJ, et al. Apremilast monotherapy in DMARD-naive psoriatic arthritis patients: results of the randomized, placebo-controlled PALACE 4 trial. Rheumatology (Oxford). 2018. PMID: 29635379. doi:10.1093/rheumatology/key032

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。